T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years.

Abstract

T-cell large granular lymphocytic (T-LGL) leukemia is characterized by cytopenia and clonal proliferation of large granular lymphocytes. We identified 26 patients with T-LGL leukemia seen at our institution over a period of 8 years. The majority of the patients were asymptomatic at diagnosis. Nine patients were treated with cyclosporine; one achieved a complete remission, and four had a hematological response. Other treatment modalities included single agent alemtuzumab, alemtuzumab combined with pentostatin, fludarabine, and combination of fludarabine and cyclophosphamide. Significant responses were not seen with any of these treatment regimens. We conclude that cyclosporine therapy may be beneficial for T-LGL leukemia patients. New treatment modalities are needed for these patients.

• Authors: Ahmed Aribi, Yang Huh, Michael Keating, Susan O'brien, Alessandra Ferrajoli, Stefan Faderl, William Wierda, Hagop Kantarjian, Farhad Ravandi
• Journal: Leukemia research (Leuk Res) Vol. 31 Issue 7 Pg. 939-45 (Jul 2007) ISSN: 0145-2126 [Print] England
• PMID: 17045649 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Antibodies, Neoplasm
• Antineoplastic Agents
• Pentostatin
• Alemtuzumab
• Cyclosporine
• Vidarabine
• fludarabine

Topics

• Adult
• Aged
• Alemtuzumab
• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Humanized
• Antibodies, Neoplasm (therapeutic use)
• Antineoplastic Agents (therapeutic use)
• Cyclosporine (therapeutic use)
• Female
• Flow Cytometry
• Humans
• Immunophenotyping
• Leukemia, Lymphoid (drug therapy, pathology)
• Leukemia, T-Cell (drug therapy, pathology)
• Male
• Middle Aged
• Pentostatin (therapeutic use)
• Retrospective Studies
• Vidarabine (analogs & derivatives, therapeutic use)